<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01569568</url>
  </required_header>
  <id_info>
    <org_study_id>UCRDC 5107</org_study_id>
    <nct_id>NCT01569568</nct_id>
  </id_info>
  <brief_title>Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI</brief_title>
  <official_title>Investigation of Brain Nitrogen in Partial Ornithine Transcarbamylase Deficiency (OTCD) Using 1 H MRS, DTI, and fMRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrea Gropman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use various types of MRI and cognitive testing to evaluate
      changes in the brain and cognitive function that occur in subjects with ornithine
      transcarbamylase deficiency (OTCD) relative to healthy individuals
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall goal of this project is to characterize metabolic, structural and cognitive
      changes in OTCD using 1H MRS, DTI, volumetric averaging and fMRI with cognitive testing of
      executive function measures to validate biomarkers for the effect of HA and its treatment on
      the brain.

      The investigators will measure gln and mI in blood and brain (using 1H MRS) in affected
      participants, and mI in brain in controls, fractional anisotropy as a measure of white matter
      microstructural damage (by DTI) and brain activation pathways alterations with tasks probing
      working memory (fMRI). As a secondary outcome measure, the investigators will correlate the
      findings from neuroimaging with cognitive functioning. This protocol is based on the previous
      5104 protocol, now includes children to evaluate the age and stage of disease on these
      indices in a cohort that is undergoing important developmental events against an age matched
      typically developing cohort.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Glutamine and Myoinositol</measure>
    <time_frame>Baseline</time_frame>
    <description>Concentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point.
Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Connectivity of Assessed by Resting-state fMRI</measure>
    <time_frame>Baseline</time_frame>
    <description>Investigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher's r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fractional Anisotropy Assessed Using DTI</measure>
    <time_frame>Baseline</time_frame>
    <description>Fractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neuropsychological Assessment</measure>
    <time_frame>Baseline</time_frame>
    <description>Testing consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Ornithine Transcarbamylase Deficiency</condition>
  <arm_group>
    <arm_group_label>Subjects with OTCD</arm_group_label>
    <description>males and females ages 7-60 years with OTCD who are able to undergo MRI and cognitive testing MRI scanning
1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>males and females ages 7-60 years who are healthy controls who are able to undergo MRI and cognitive testing MRI scanning
1H MRS, DTI, FMRI Cognitive testing Neuropsychological testing</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI scanning</intervention_name>
    <description>1H MRS, DTI, FMRI</description>
    <arm_group_label>Subjects with OTCD</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive testing</intervention_name>
    <description>Behavioral testing</description>
    <arm_group_label>Subjects with OTCD</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Males and females, ages 7-60 years with ornithine transcarbamylase deficiency Males and
        females, ages 7-60 years who are healthy controls without ornithine transcarbamylase
        deficiency
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subject inclusion criteria:

          1. Patients with OTCD;

          2. Age range: 7-60 years

          3. Able to undergo neuroimaging safely (i.e. without presence of ferromagnetic devices)

          4. Subject has a documented full scale IQ &gt; 70

        Control participant inclusion criteria:

          1. Healthy males and females without metabolic disease aged 7-60 years

          2. Subject has a documented full scale IQ &gt; 70

        Exclusion Criteria:

        Subject exclusion criteria:

          1. Mental retardation (i.e., Full Scale IQ&lt; 70)

          2. Age range &lt;7 or &gt;60 years

          3. Presence of ferromagnetic device(s) that preclude safe imaging

          4. Pregnant female

        Control exclusion criteria:

          1. Subjects with a documented history of an intellectual deficit (i.e., Full Scale IQ&lt;
             70)

          2. Age range &lt;7 or &gt;60 years

          3. Presence of ferromagnetic device(s) that preclude safe imaging

          4. Pregnant female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea L Gropman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Research Institute</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://NUCDF.org</url>
    <description>Family support group</description>
  </link>
  <link>
    <url>http://rarediseasesnetwork.epi.usf.edu/ucdc/</url>
    <description>Urea cycle consortium site</description>
  </link>
  <reference>
    <citation>Gropman AL, Shattuck K, Prust MJ, Seltzer RR, Breeden AL, Hailu A, Rigas A, Hussain R, VanMeter J. Altered neural activation in ornithine transcarbamylase deficiency during executive cognition: an fMRI study. Hum Brain Mapp. 2013 Apr;34(4):753-61. doi: 10.1002/hbm.21470. Epub 2011 Nov 23.</citation>
    <PMID>22110002</PMID>
  </reference>
  <reference>
    <citation>Prust MJ, Gropman AL, Hauser N. New frontiers in neuroimaging applications to inborn errors of metabolism. Mol Genet Metab. 2011 Nov;104(3):195-205. doi: 10.1016/j.ymgme.2011.06.020. Epub 2011 Jun 30. Review.</citation>
    <PMID>21778100</PMID>
  </reference>
  <reference>
    <citation>Gropman AL, Gertz B, Shattuck K, Kahn IL, Seltzer R, Krivitsky L, Van Meter J. Diffusion tensor imaging detects areas of abnormal white matter microstructure in patients with partial ornithine transcarbamylase deficiency. AJNR Am J Neuroradiol. 2010 Oct;31(9):1719-23. doi: 10.3174/ajnr.A2122. Epub 2010 May 20.</citation>
    <PMID>20488904</PMID>
  </reference>
  <reference>
    <citation>Gropman A. Brain imaging in urea cycle disorders. Mol Genet Metab. 2010;100 Suppl 1:S20-30. doi: 10.1016/j.ymgme.2010.01.017. Epub 2010 Feb 13. Review.</citation>
    <PMID>20207564</PMID>
  </reference>
  <reference>
    <citation>Oldham MS, VanMeter JW, Shattuck KF, Cederbaum SD, Gropman AL. Diffusion tensor imaging in arginase deficiency reveals damage to corticospinal tracts. Pediatr Neurol. 2010 Jan;42(1):49-52. doi: 10.1016/j.pediatrneurol.2009.07.017.</citation>
    <PMID>20004862</PMID>
  </reference>
  <reference>
    <citation>Gropman AL, Sailasuta N, Harris KC, Abulseoud O, Ross BD. Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults. Radiology. 2009 Sep;252(3):833-41. doi: 10.1148/radiol.2523081878. Epub 2009 Jun 30.</citation>
    <PMID>19567648</PMID>
  </reference>
  <reference>
    <citation>Gropman AL, Fricke ST, Seltzer RR, Hailu A, Adeyemo A, Sawyer A, van Meter J, Gaillard WD, McCarter R, Tuchman M, Batshaw M; Urea Cycle Disorders Consortium. 1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency. Mol Genet Metab. 2008 Sep-Oct;95(1-2):21-30. doi: 10.1016/j.ymgme.2008.06.003. Epub 2008 Jul 26.</citation>
    <PMID>18662894</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2012</study_first_posted>
  <results_first_submitted>June 30, 2015</results_first_submitted>
  <results_first_submitted_qc>April 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 14, 2017</results_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Andrea Gropman</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Neuroimaging</keyword>
  <keyword>MRI</keyword>
  <keyword>Urea cycle</keyword>
  <keyword>hyperammonemia</keyword>
  <keyword>cognitive function</keyword>
  <keyword>ornithine transcarbamylase deficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ornithine Carbamoyltransferase Deficiency Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Final data is on the UCDC website</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects With OTCD</title>
          <description>males and females ages 7-60 years with OTCD
MRI scanning: 1H Magnetic Resonance Spectroscopy (MRS), Diffusion Tensor Imaging (DTI), functional magnetic resonance imaging (fMRI)
Cognitive testing: Neuropsychological testing</description>
        </group>
        <group group_id="P2">
          <title>Healthy Controls</title>
          <description>males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With OTCD</title>
          <description>males and females ages 7-60 years with OTCD
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
        </group>
        <group group_id="B2">
          <title>Healthy Controls</title>
          <description>males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.3" spread="19.4"/>
                    <measurement group_id="B2" value="25.8" spread="14.6"/>
                    <measurement group_id="B3" value="28.05" spread="17.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentration of Glutamine and Myoinositol</title>
        <description>Concentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point.
Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM).</description>
        <time_frame>Baseline</time_frame>
        <population>Two OTCD patients and one healthy control were excluded due to excessive head motion.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With OTCD</title>
            <description>males and females ages 7-60 years with OTCD
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Glutamine and Myoinositol</title>
          <description>Concentration based on area under curve on 1H Magnetic Resonance Spectroscopy(MRS) and quantitated by LCModel (a method that allows automatic quantitation of spectroscopy data). A metabolite's tissue concentration is related to the integrated amplitude, the area under the curve of the MRS signal, it produces. While MRS signals are usually acquired in the time domain as free induction decays or echoes, they are usually viewed and analyzed in the frequency domain. The frequency domain representation is derived from the acquired time domain data by the Fourier Transform. The protocol we use selects 257 averages. The machine summates the data at each time point to generate one value for the area under the curve. Therefore, we don't have the measurement at each time point.
Furthermore, we measured voxels in two different brain areas containing different kinds of brain matter: one voxel was located in posterior cingulate gray matter (PCGM) and the other in parietal white matter (PWM).</description>
          <population>Two OTCD patients and one healthy control were excluded due to excessive head motion.</population>
          <units>mM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Concentration of glutamine in PWM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.61" spread="1.07"/>
                    <measurement group_id="O2" value="1.66" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration of myoinositol in PWM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="0.84"/>
                    <measurement group_id="O2" value="2.69" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration of glutamine in PCGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.22" spread="1.70"/>
                    <measurement group_id="O2" value="3.62" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Concentration of myoinositol in PCGM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="0.80"/>
                    <measurement group_id="O2" value="4.37" spread="0.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that the concentration of glutamine is the same for controls and OTCD patients in PCGM.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori threshold is 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that the concentration of myoinositol is the same for controls and OTCD patients in PCGM.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold is 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that the concentration of glutamine is the same for controls and OTCD patients in PWM.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori threshold was 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that the concentration of myoinositol is the same for controls and OTCD patients in PWM.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori threshold was 0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Functional Connectivity of Assessed by Resting-state fMRI</title>
        <description>Investigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher’s r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO).</description>
        <time_frame>Baseline</time_frame>
        <population>Resting state data was not acquired for several of our participants (7 controls and 4 patients). Furthermore, 3 OTCD patients were excluded from the analyses due to excessive head motion.</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With OTCD</title>
            <description>males and females ages 7-60 years with OTCD
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Connectivity of Assessed by Resting-state fMRI</title>
          <description>Investigation of differences in functional connectivity of OTCD patients compared to healthy controls, particularly in the default-mode network (DMN) and the set-maintenance network (SMN). Participants underwent a resting-state scan using 3T fMRI. Combining independent component analysis (ICA) and region-of-interest (ROI) analyses, identified the nodes that comprised each network in each group, and assessed internodal connectivity. For each subject, this analysis generated a correlation value, which reflected the strength of functional connectivity between each ROI pair.The correlation r-values were normalized using Fisher’s r-to-Z-transform, generating z-scores. The DMN was composed of 1) anterior cingulate/medial prefrontal cortex (ACC/mPFC), 2) posterior cingulate cortex (PCC), and 3) bilateral inferior parietal lobule (IPL). The SMN was composed of 1)ACC, 2) bilateral superior frontal gyrus (SFG), and 3) bilateral anterior insula/frontal operculum (aI/fO).</description>
          <population>Resting state data was not acquired for several of our participants (7 controls and 4 patients). Furthermore, 3 OTCD patients were excluded from the analyses due to excessive head motion.</population>
          <units>z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DMN: ACC/mPFC &amp; left IPL connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.86" spread="0.70"/>
                    <measurement group_id="O2" value="0.18" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMN: ACC/mPFC &amp; PCC connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.70"/>
                    <measurement group_id="O2" value="0.12" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMN: ACC/mPFC &amp; right IPL connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.53"/>
                    <measurement group_id="O2" value="0.07" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMN: PCC &amp; left IPL connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.69" spread="0.63"/>
                    <measurement group_id="O2" value="0.69" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMN: PCC &amp; right IPL connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="0.42"/>
                    <measurement group_id="O2" value="0.64" spread="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DMN: left IPL &amp; right IPL connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" spread="0.69"/>
                    <measurement group_id="O2" value="0.70" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: ACC &amp; left aI/fO connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.39"/>
                    <measurement group_id="O2" value="0.28" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: ACC &amp; left SFG connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.35"/>
                    <measurement group_id="O2" value="0.44" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: ACC &amp; right aI/fO connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.21" spread="0.30"/>
                    <measurement group_id="O2" value="0.44" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: ACC &amp; right SFG connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.37"/>
                    <measurement group_id="O2" value="0.59" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: left aI/fO &amp; left SFG connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.35"/>
                    <measurement group_id="O2" value="0.22" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: left aI/fO &amp; right aI/fO connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.43"/>
                    <measurement group_id="O2" value="0.80" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: left aI/fO &amp; right SFG connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.33"/>
                    <measurement group_id="O2" value="0.11" spread="0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: left SFG &amp; right SFG connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.70" spread="0.43"/>
                    <measurement group_id="O2" value="0.68" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: right aI/fO &amp; left SFG connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.22"/>
                    <measurement group_id="O2" value="0.25" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SMN: right aI/fO &amp; right SFG connectivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.26"/>
                    <measurement group_id="O2" value="0.27" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states predicts no main effects of Group, ROI pair, or Age, suggesting that the connectivity between all DMN nodes is the same across groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Our a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a 2 (Group) x 6 (ROI Pair) ANOVA to assess functional connectivity between the nodes of the DMN, using age as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the ACC/mPFC node and the left IPL node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.024</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the ACC/mPFC node and the PCC node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.040</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold is 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the ACC/mPFC node and the right IPL node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.008</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the left IPL node and the right IPL node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.470</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the PCC node and the left IPL node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.829</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the PCC node and the right IPL node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.801</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis states predicts no main effects of Group, ROI pair, or Age, suggesting that the connectivity between all SMN nodes is the same across groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Our a priori threshold for statistical significance was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a 2 (Group) x 6 (ROI Pair) ANOVA to assess functional connectivity between the nodes of the SMN, using age as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the ACC node and the left aI/fO node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.550</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the ACC node and the left SFG node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.113</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the ACC node and the right aI/fO node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the ACC node and the right SFG node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the left aI/fO and the left SFG node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.426</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the left aI/fO node and the right aI/fO node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.256</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the left aI/fO and the right SFG node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.853</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the right aI/fO node and the left SFG node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis predicts that functional connectivity between the right aI/fO node and the right SFG node does not differ between groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.023</p_value>
            <p_value_desc>This is an uncorrected p-value. A priori significance threshold was 0.05.</p_value_desc>
            <method>ANOVA</method>
            <method_desc>We ran a series of post-hoc one-way ANOVAs to localize the main effect found. Age was used as a covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fractional Anisotropy Assessed Using DTI</title>
        <description>Fractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With OTCD</title>
            <description>males and females ages 7-60 years with OTCD
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
        </group_list>
        <measure>
          <title>Fractional Anisotropy Assessed Using DTI</title>
          <description>Fractional Anisotropy (FA) is a measure of the diffusion asymmetry within a voxel as defined by its eigenvalues. In our study, FA is being used as a measure of white matter integrity, because FA is very sensitive to small microstructural changes.Fractional anisotropy (FA) is a scalar value between zero and one (0-1) that describe anisotropy of a diffusion process. A value of zero means that diffusion is isotropic, i.e. it is unrestricted (or equally restricted) in all directions. A value of one means that diffusion occurs only along one axis and is fully restricted along all other directions.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="0.003"/>
                    <measurement group_id="O2" value="0.3" spread="0.008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neuropsychological Assessment</title>
        <description>Testing consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales.</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With OTCD</title>
            <description>males and females ages 7-60 years with OTCD
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
          <group group_id="O2">
            <title>Healthy Controls</title>
            <description>males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
          </group>
        </group_list>
        <measure>
          <title>Neuropsychological Assessment</title>
          <description>Testing consisted of the Wechsler Abbreviated Scale of Intelligence (WASI), Comprehensive Trail Making Test (CTMT) (range 17-87), and the Behavioral Rating Inventory of Executive Function (BRIEF) (range GEC: 70-210; BRI:39-82 ; MI:41-92). The WASI includes three measures of intelligence; including, performance IQ (sum of block design and matrices sub scales; range: 40-160), verbal IQ (sum of vocabulary and similarities sub scales; range 40-160), and total IQ (sum of all four subscales; range: 80-320). The CTMT measures simple attention and executive function, it consists of five dot to dots that increase with complexity and difficulty. Higher values indicate better outcomes for all scales.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WASI - Verbal IQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.33" spread="14.52"/>
                    <measurement group_id="O2" value="107.77" spread="18.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WASI - Performance IQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" spread="13.14"/>
                    <measurement group_id="O2" value="112.59" spread="14.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WASI - Full IQ</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.28" spread="14.02"/>
                    <measurement group_id="O2" value="111.22" spread="16.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trails - Composite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48" spread="15"/>
                    <measurement group_id="O2" value="47" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brief - Behavioral Regulation Index (BRI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.59" spread="9.49"/>
                    <measurement group_id="O2" value="46.73" spread="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brief - Metacognition Index (MI)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.45" spread="11.75"/>
                    <measurement group_id="O2" value="47.38" spread="8.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brief - Global Executive Composite Score (GEC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.05" spread="10.37"/>
                    <measurement group_id="O2" value="46.88" spread="7.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.929</p_value>
            <p_value_desc>Equal variance is not assumed. Two tailed t-test WASI verbal IQ between cases and controls</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.002</p_value>
            <p_value_desc>Equal variance not assumed. Comparison WASI performance IQ cases and controls</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.094</p_value>
            <p_value_desc>Equal variance not assumed. Comparison of WASI full IQ cases and controls</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.853</p_value>
            <p_value_desc>Equal variance not assumed. Comparison of CTMT global composite score between cases and controls</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.001</p_value>
            <p_value_desc>Equal variance not assumed. Comparison of BRIEF BRI cases and controls</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <p_value_desc>Equal variances not assumed. Comparison of BRIEF MI cases and controls</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Equal variances not assumed. Comparison of BRIEF GEC between cases and controls.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects With OTCD</title>
          <description>males and females ages 7-60 years with OTCD
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
        </group>
        <group group_id="E2">
          <title>Healthy Controls</title>
          <description>males and females ages 7-60 years who are healthy controls
MRI scanning: 1H MRS, DTI, FMRI
Cognitive testing: Neuropsychological testing</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrea Gropman</name_or_title>
      <organization>Children's National Medical Center</organization>
      <phone>202-476-2120</phone>
      <email>agropman@childrensnational.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

